Trials / Completed
CompletedNCT05923541
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
Clinical Study on Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD13-02 cell infusion | Universal CAR-T cells targeting CD7 |
Timeline
- Start date
- 2023-06-26
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
- First posted
- 2023-06-28
- Last updated
- 2024-11-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05923541. Inclusion in this directory is not an endorsement.